POP Act
- Bill Number
- S. 2836
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Commerce
- Status
- Introduced
- Latest Action
- 2025-09-17: Read twice and referred to the Committee on the Judiciary.
- Last Updated
- 2025-12-09T22:13:56Z
AI-Generated Summary
Purpose
The "Patients Over Profit Act" (S. 2836), also known as the "POP Act," aims to prevent conflicts of interest in the U.S. health care system by prohibiting common ownership or control between health insurance companies and certain Medicare-funded health care providers. This is intended to prioritize patient care over corporate profits, reduce potential incentives for insurers to limit services from providers they own, and promote fair competition in Medicare services.
Key Provisions
- Prohibition on Common Ownership: It is illegal for any person (individual or entity) to directly or indirectly own, operate, or control both:
- A "health insurance issuer" (a company that sells health insurance plans, as defined under federal law).
- An "applicable provider" (non-hospital entities like physician groups or clinics that bill Medicare Part B for outpatient services or provide services under Medicare Advantage plans) or a "management services organization" (MSO, an entity that provides administrative support to providers via a management services agreement).
- Divestment Requirements: Entities in violation must sell off (divest) either the provider/MSO or the insurance issuer:
- Within 2 years for ownership acquired before the law's enactment.
- Within 1 year for ownership acquired after enactment.
- Enforcement and Penalties:
- Civil lawsuits can be filed by the Inspector General of the Department of Health and Human Services (HHS), the Department of Justice's (DOJ) Antitrust Division, the Federal Trade Commission (FTC), or state attorneys general.
- Courts can order violators to stop the practice, divest assets, and return (disgorge) any profits earned from health care services during the violation period.
- Disgorged funds are deposited into an FTC-managed fund to support health care needs in affected communities, without limiting individuals' rights to pursue separate claims.
- FTC Oversight:
- Divestitures must be reported to the FTC and DOJ Antitrust Division for review under antitrust laws (like the Clayton Act, which requires waiting periods for mergers to check for anti-competitive effects), even if below normal size thresholds.
- The FTC and DOJ will assess impacts on competition, financial stability, and public interest for each divestiture and any follow-on acquisitions.
- The FTC must issue rules to implement the law, without weakening its requirements.
- Medicare-Specific Rules (Amendments to the Social Security Act):
- Starting January 1, 2026, HHS cannot contract with or pay Medicare Advantage (MA) organizations (private plans under Medicare Part C) if they violate the ownership prohibition.
- MA organizations must certify compliance and provide related information to HHS.
- Violations in MA or Medicare Part D (prescription drug plans) count as false claims under federal fraud laws, potentially leading to penalties.
- Medicare Part D plans are cross-referenced to adopt the same prohibition.
- Definitions and Exclusions:
- Applicable providers exclude hospitals, critical access hospitals, rural emergency hospitals, durable medical equipment suppliers, and pharmacies.
- "Person" follows the broad definition under antitrust law (includes corporations and individuals).
The law does not limit existing enforcement powers of the FTC, DOJ, HHS, or states.
Significant Changes to Existing Law
- Introduces a new nationwide ban on common ownership between insurers and specific Medicare providers, which was not previously prohibited under federal law (though antitrust laws like the Sherman and Clayton Acts address mergers generally).
- Adds targeted amendments to Medicare statutes (Sections 1857 and 1860D-12 of the Social Security Act), linking violations to contract ineligibility, payment denials, and false claims liability—expanding beyond general antitrust enforcement.
- Mandates FTC rulemaking and enhanced pre- and post-divestiture reviews, bypassing some antitrust thresholds to scrutinize smaller health care deals.
- Creates a disgorgement mechanism with community-focused fund distribution, a novel addition to health care enforcement.
Potential Impacts
- On Government Agencies: Increases workload for HHS (contract oversight and certifications), DOJ/FTC (reviews and lawsuits), and state attorneys general (enforcement options). Could lead to more resources needed for monitoring Medicare Advantage and Part D plans, potentially reducing fraudulent claims.
- On Citizens: Medicare beneficiaries may benefit from reduced incentives for insurers to deny or limit care from owned providers, possibly improving access and quality in outpatient services. However, divestitures could temporarily disrupt provider networks or raise costs if markets consolidate differently.
- On Businesses: Forces restructuring in vertically integrated health care firms (e.g., insurers owning doctor groups), potentially affecting thousands of entities in Medicare. No direct impact on international relations, as it focuses on domestic U.S. health insurance and Medicare.
Main Stakeholders Affected
- Health Insurance Issuers: Especially Medicare Advantage and Part D plan sponsors, who may need to divest provider ownership or lose federal contracts.
- Applicable Providers and MSOs: Physician practices, outpatient clinics, and administrative support firms under Medicare Part B/C, facing ownership restrictions and potential forced sales.
- Medicare Beneficiaries: Older adults and disabled individuals relying on Medicare, who could see changes in care access and costs.
- Government Entities: HHS (Medicare administration), FTC/DOJ (antitrust enforcement), and state governments (litigation and consumer protection).
- Health Care Communities: Local providers and patients in areas with integrated insurer-provider models, benefiting from disgorged funds for services.
Notable Legal, Constitutional, or Political Implications
- Legal: Bolsters antitrust application to health care by creating specific prohibitions and tying them to Medicare fraud laws, potentially increasing civil penalties and lawsuits. May invite challenges under administrative law if FTC rules are seen as overreaching.
- Constitutional: Could face scrutiny for implicating property rights (e.g., forced divestitures as a "taking" under the Fifth Amendment), though similar antitrust remedies have been upheld. No direct free speech or equal protection issues apparent.
- Political: Addresses concerns over corporate consolidation in health care, aligning with efforts to curb profiteering in Medicare (a major federal program). As a Senate-introduced bill by Democrats, it may spark debates on government intervention in private markets versus protecting vulnerable patients.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (2)
Sen. Warren, Elizabeth [D-MA], Sen. Markey, Edward J. [D-MA]
Recent Actions
- 2025-09-17: Read twice and referred to the Committee on the Judiciary.
- 2025-09-17: Introduced in Senate
Bill Versions
- Patients Over Profit Act — issued 2025-09-17 — PDF (11 pages)